Regulations regarding clinical trials have recently changed. These changes are to ensure transparency of the process and increase credibility. Changes include:

Clinical trials are one of the most important elements in research and modern healthcare. It is through clinical trials that medications are tested and their effectiveness established. Without the trials, it would be challenging to make any modern-day medical breakthroughs.

Those at work and innovating in the realms of clinical trials, drug development, and pharma face the largest challenges of their careers. But they do so armed with some of the finest medical tools ever known to man, empowered by opportunities never imagined before.

Clinical trials require recruitment, retention, and engagement. Recruitment is one of the most challenging factors, and one that must be must overcome if anything good is to be accomplished. Poor recruitment results in trial delays, which can lead to financial loses. Recruitment of too few test subjects also creates the potential for presenting biased results; more test participants are needed in order to present comprehensive and conclusive results. Here is why patient recruitment presents a challenge to the recruiters:

Clinical trials are arguably the most important phase of the pharmaceutical development process; scientists get to see how their drugs work in real life and make important improvements. There are many recent innovations in the medical field that are completely transforming the way we conduct clinical trials, which means important new drugs are safer and get to the market faster. Here are five of the most important innovations that are changing clinical trials today:

Remote patient monitoring (RPM) has resulted in great improvement in the experience of both clinicians and the patients. Doctors now have greater ability to easily access patient details, higher quality of healthcare delivery, and reduced risks for the patients. Innovations around RPM cover many health conditions in a wide geographical location.